Origami™ B(DE3)pLysS Competent Cells 
Origami™ B host strains carry the same mutations in trxB and gor as the original Origami strains, except that they are derived from a lacZY mutant of BL21 to enable precise control of expression levels by adjusting the concentration of IPTG. Thus the Origami B strains combine the desirable characteristics of BL21, Tuner™, and Origami strains in one strain background. The mutations in trxB and gor are selectable on kanamycin and tetracycline, respectively; therefore, these strains cannot be used with plasmids that can only selected with kanamycin or tetracycline. These strains also include the lon and ompT deficiences of BL21, which increase protein stability.
DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.
pLysS strains express T7 lysozyme, which further suppresses basal expression of T7 RNA polymerase prior to induction, thus stabilizing pET recombinants encoding target proteins that affect cell growth and viability. Genotype: F-ompT hsdSB(rB- mB-) gal dcm lacY1 ahpC (DE3) gor522:: Tn10 trxB pLysS (CamR, KanR, TetR)
相關(guān)產(chǎn)品
70836  Origami™ B Competent Cells
70837  Origami™ B(DE3) Competent Cells
70911  Origami™ B Competent Cell Set
產(chǎn)品信息
Components 
0.4 ml 1 ml Component
• 2 × 0.2 ml 5 × 0.2 ml Origami B(DE3)pLysS Competent Cells
• 2 × 2 ml 4 × 2 ml SOC Medium
• 2 ng 2 ng Test Plasmid
Guaranteed efficiency  Guaranteed efficiency: > 2 x 106 cfu/μg
商店和運輸信息
Storage  ≤ -70°C
Ship  Dry Ice Only
Multiple Toxicity Values, refer to MSDS
Licence Brookhaven  This product is covered under license from Brookhaven National Labs. Commercial entities need to obtain a research use license prior to purchase. Please contact your licensing department to confirm that your company already holds a research use license.